We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Non-Invasive Diagnostic Test Improves Detection of Oral Cancer

By LabMedica International staff writers
Posted on 04 Apr 2023

Oral squamous cell carcinoma (OSCC) is a highly prevalent type of cancer that affects the lining of the mouth and throat, and is strongly associated with lifestyle factors such as smoking, alcohol use, or poor oral hygiene. More...

Symptoms of OSCC include persistent mouth sores, difficulty swallowing, and changes in speech. The disease can be successfully treated if detected early, but prognosis is poor if diagnosed at a late stage. Oral epithelial dysplasia (OED) is a precursor condition to OSCC, in which the lining of the mouth shows abnormal changes in shape, size, and arrangement due to lifestyle factors such as smoking or alcohol use. OED can progress to oral cancer if not detected and treated early. With more than three hundred thousand people worldwide being diagnosed with oral cancer, the mortality rate of around 50% is alarming, indicating a lack of effective tools for early detection.

Now, scientists at the University of Surrey (Guildford, UK) have developed PANDORA, a proof-of-concept test that demonstrated over 92% accuracy in identifying patients with OSCC and over 80% accuracy in detecting pre-cancer or OED. The study involved taking cell samples from a test group of 40 people with OSCC and OED, as well as 79 people without cancer, including those with other benign lesions. The DEPtech 3DEP analyzer, with a unique set-up protocol, was utilized to measure and analyze the patient's cells. Since samples can be obtained at a dentist's office and sent for analysis via post, the test can be used in primary care to identify patients requiring specialist care.

“Over three hundred thousand people are diagnosed with oral cancer worldwide – a disease with an alarming mortality rate of around 50%,” said Dr. Fatima Labeed, co-author of the study and Senior Lecturer in Human Biology from the University of Surrey. “This suggests that the scientific community doesn't have the tools available to identify oral cancer early enough, and we hope that PANDORA paves the way for more effective clinical diagnostic tools for this terrible disease.”

Related Links:
University of Surrey


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The precision oncology test identifies patients most at risk of undergoing severe toxicity from treatment with 5FU/capecitabine (Photo courtesy of 123RF)

Precision Oncology Test Predicts Patient Toxicity Before Beginning Chemotherapy

5-fluorouracil (5FU) and capecitabine have been cornerstone chemotherapeutic agents for over four decades, effectively treating a variety of cancers. However, 5FU/capecitabine can cause varying degrees... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.